Vaccination against GIP for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: According to the WHO, more than 1 billion people worldwide are overweight and at risk of developing chronic illnesses, including cardiovascular disease, type 2 diabetes, hypertension and stroke. Current therapies show limited efficacy and are often associated with unpleasant side-effect profiles, hence there is a medical need for new therapeutic interventions in the field of obesity. Gastric inhibitory peptide (GIP, also known as glucose-dependent insulinotropic polypeptide) has recently been postulated to link over-nutrition with obesity. In fact GIP receptor-deficient mice (GIPR(-/-)) were shown to be completely protected from diet-induced obesity. Thus, disrupting GIP signaling represents a promising novel therapeutic strategy for the treatment of obesity. METHODOLOGY/PRINCIPAL FINDINGS: In order to block GIP signaling we chose an active vaccination approach using GIP peptides covalently attached to virus-like particles (VLP-GIP). Vaccination of mice with VLP-GIP induced high titers of specific antibodies and efficiently reduced body weight gain in animals fed a high fat diet. The reduction in body weight gain could be attributed to reduced accumulation of fat. Moreover, increased weight loss was observed in obese mice vaccinated with VLP-GIP. Importantly, despite the incretin action of GIP, VLP-GIP-treated mice did not show signs of glucose intolerance. CONCLUSIONS/SIGNIFICANCE: This study shows that vaccination against GIP was safe and effective. Thus active vaccination may represent a novel, long-lasting treatment for obesity. However further preclinical safety/toxicology studies will be required before the therapeutic concept can be addressed in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GIP antagonism is also a potential obesity treatment as in preclinical studies improved the metabolic profile and reduced food intake [54–56].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [55]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795 · cited 1×
“society [1].”
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101 · cited 1×
“The PCR product was then cloned into pBP [48].”
MethodNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 1×
“Interestingly, GIP has been reported to have a reduced incretin effect in type II diabetic patients whereas the insulinotropic effect of GLP is preserved in this patient population [43–45].”
BackgroundBeneficial health effects of modest weight loss.
Dj, G. (1992) · PubMed · Cited by 1,263
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 4×
“These findings are in accordance with previous findings in GIPR mice showing little [17] or no difference [32] in age-related body weight gain in mice fed normal chow.”
BackgroundResultInfluentialSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860 · cited 1×
“Likewise, the incretin activity of GIP and GLP1 is well established in humans [37–39].”
BackgroundJohnson, R. N., Metcalf, P. A., & Baker, J. R. (1983) · Clinica Chimica Acta · doi:10.1016/0009-8981(83)90078-5 · Cited by 763 · cited 1×
“Fructosamine levels provide a retrospective reading of blood glucose for the 2 weeks prior to measurement [30,31].”
BackgroundThe Influence of Antigen Organization on B Cell Responsiveness
Bachmann, M. F., Rohrer, U. H., Kündig, T. M., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1993) · Science · doi:10.1126/science.8248784 · Cited by 717 · cited 1×
“We have previously shown that antigens displayed on highly repetitive viral surfaces can break B cell tolerance [21] and epitopes displayed on the surface of virus-”
BackgroundSelf-citationNauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 667 · cited 1×
“Based on these observations DPP-IV inhibitors have been developed and drugs like Sitagliptin and Vildagliptin are now on the market as a novel class of type II diabetes drugs [40–42].”
BackgroundEarly Mortality Among Medicare Beneficiaries Undergoing Bariatric Surgical Procedures
Flum, D. R. (2005) · JAMA · doi:10.1001/jama.294.15.1903 · Cited by 633 · cited 1×
“surgery [8].”
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 1×
“Interestingly, GIP has been reported to have a reduced incretin effect in type II diabetic patients whereas the insulinotropic effect of GLP is preserved in this patient population [43–45].”
BackgroundEffect of Degree of Weight Loss on Health Benefits
Blackburn, G. (1995) · Obesity Research · doi:10.1002/j.1550-8528.1995.tb00466.x · Cited by 503
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“In fact, GIPR mice have been reported to display signs of glucose intolerance [34].”
BackgroundAhrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Elahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 309 · cited 1×
“Likewise, the incretin activity of GIP and GLP1 is well established in humans [37–39].”
BackgroundCirculation and Degradation of GIP and GLP-1
Deacon, C. F. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826160 · Cited by 299 · cited 1×
“Considering that the first two N-terminal amino acids of GIP are rapidly cleaved by dipeptidyl peptidase (DPP)-IV [28] in vivo we wanted to test whether the induced immune response by our vaccine also recognizes the N-terminally cleaved form of GIP which has been shown to be a partial antagonist of GIP in vitro [29].”
BackgroundExtrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290 · cited 2×
“These findings are in accordance with previous findings in GIPR mice showing little [17] or no difference [32] in age-related body weight gain in mice fed normal chow.”
BackgroundResultGIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266 · cited 1×
“The role of GIP in glucose and lipid metabolism is well documented in several animal species [12,36].”
BackgroundOral Glucose Augmentation of Insulin Secretion
Andersen, D. K., Elahi, D., Brown, J. C., Tobin, J. D., & Andres, R. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109100 · Cited by 240 · cited 1×
“Likewise, the incretin activity of GIP and GLP1 is well established in humans [37–39].”
BackgroundMcClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 239 · cited 1×
“challenge and feeding, suggesting that in severely obese mice antagonism of GIP is even beneficial for glucose homeostasis [20].”
BackgroundFunctional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237 · cited 1×
“Moreover, GIP receptors are expressed on adipocytes [16] consistent with a direct role of GIP on these cells.”
BackgroundMeier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230 · cited 1×
“Interestingly, GIP has been reported to have a reduced incretin effect in type II diabetic patients whereas the insulinotropic effect of GLP is preserved in this patient population [43–45].”
BackgroundJEGERLEHNER, A. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00266-9 · Cited by 226 · cited 11×
“To overcome GIP-specific B cell unresponsiveness, we covalently coupled peptides consisting of the first 15 amino acids of mature GIP to the highly repetitive surface of bacteriophage Qb VLPs [24,27] (Figure 1A).”
MethodInfluentialGut peptides and the regulation of appetite
Huda, M. S. B., Wilding, J. P. H., & Pinkney, J. H. (2006) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00245.x · Cited by 223 · cited 1×
“food intake and energy balance has substantially improved [9–11].”
BackgroundAmbühl, P. M., Tissot, A. C., Fulurija, A., Maurer, P., Nussberger, J., Sabat, R., Nief, V., Schellekens, C., Sladko, K., Roubicek, K., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e32800ff5d6 · Cited by 219 · cited 1×
“like particles (VLPs) are able to efficiently induce self-specific antibody responses in mice and humans [22–26].”
BackgroundSelf-citationGastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219 · cited 1×
“Specifically, GIP has been shown to promote triglyceride clearance from the circulation [13,14], a process partly mediated by its ability to stimulate lipoprotein lipase activity [15].”
BackgroundVaccination against IL‐17 suppresses autoimmune arthritis and encephalomyelitis
Röhn, T. A., Jennings, G. T., Hernandez, M., Grest, P., Beck, M., Zou, Y., Kopf, M., & Bachmann, M. F. (2006) · European Journal of Immunology · doi:10.1002/eji.200636658 · Cited by 195 · cited 1×
“like particles (VLPs) are able to efficiently induce self-specific antibody responses in mice and humans [22–26].”
BackgroundSelf-citationNeutralization of IL‐17 by active vaccination inhibits IL‐23‐dependent autoimmune myocarditis
Sonderegger, I., Röhn, T. A., Kurrer, M. O., Iezzi, G., Zou, Y., Kastelein, R. A., Bachmann, M. F., & Kopf, M. (2006) · European Journal of Immunology · doi:10.1002/eji.200636484 · Cited by 167 · cited 1×
“like particles (VLPs) are able to efficiently induce self-specific antibody responses in mice and humans [22–26].”
BackgroundSelf-citationIoannides-Demos, L. L., Proietto, J., & McNeil, J. J. (2005) · Drugs · doi:10.2165/00003495-200565100-00006 · Cited by 165
Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.
Wasada, T., McCorkle, K., Harris, V, Kawai, K., Howard, B., & Unger, R. H. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110335 · Cited by 153 · cited 2×
“Specifically, GIP has been shown to promote triglyceride clearance from the circulation [13,14], a process partly mediated by its ability to stimulate lipoprotein lipase activity [15].”
BackgroundDipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes
Mest, H. ‐., & Mentlein, R. (2005) · Diabetologia · doi:10.1007/s00125-005-1707-5 · Cited by 148 · cited 1×
“Based on these observations DPP-IV inhibitors have been developed and drugs like Sitagliptin and Vildagliptin are now on the market as a novel class of type II diabetes drugs [40–42].”
BackgroundGault, V. A., McClean, P. L., Cassidy, R. S., Irwin, N., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0710-4 · Cited by 133 · cited 1×
“reported that prolonged treatment of mice fed a high fat diet with a GIP antagonist improved glucose tolerance in these animals suggesting that reducing GIP signaling could be beneficial under these circumstances [18].”
BackgroundTherapeutic vaccination for chronic diseases: a new class of drugs in sight
Bachmann, M. F., & Dyer, M. R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1284 · Cited by 125 · cited 1×
“The risk for undesired autoinflammatory responses is minimized with our vaccine [33].”
BackgroundSelf-citationInduction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles
Chackerian, B., Lowy, D. R., & Schiller, J. T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2373 · Cited by 123 · cited 1×
“like particles (VLPs) are able to efficiently induce self-specific antibody responses in mice and humans [22–26].”
BackgroundWeight management and current options in pharmacotherapy: Orlistat and sibutramine
Leung, W. Y. S., Thomas, G. N., Chan, J. C. N., & Tomlinson, B. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90009-9 · Cited by 107 · cited 1×
“unpleasant side-effect profiles [5–7].”
Irwin, N., McClean, P. L., O'Harte, F. P. M., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0692-2 · Cited by 106 · cited 1×
“Likewise, recent studies demonstrated that treatment with a GIP-receptor antagonist led to reduced weight gain in mice fed a high fat diet and weight loss in obese mice [18–20].”
Gault, V., Parker, J., Harriott, P., Flatt, P., & O'Harte, F. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750525 · Cited by 103 · cited 1×
“Considering that the first two N-terminal amino acids of GIP are rapidly cleaved by dipeptidyl peptidase (DPP)-IV [28] in vivo we wanted to test whether the induced immune response by our vaccine also recognizes the N-terminally cleaved form of GIP which has been shown to be a partial antagonist of GIP in vitro [29].”
BackgroundRecombinant rna phage qβ capsid particles synthesized and self-assembled in escherichia coli
Kozlovska, T. M., Cielēns, I., Dreilina, D., Dišlers, A., Baumanis, V., Ose, V., & Pumpēns, P. (1993) · Gene · doi:10.1016/0378-1119(93)90261-z · Cited by 99
Glycosylation of Plasma Protein and its Relation to Glycosylated Hemoglobin in Diabetes
Yue, D. K., Morris, K., McLennan, S. V., & Turtle, J. R. (1980) · Diabetes · doi:10.2337/diab.29.4.296 · Cited by 90 · cited 1×
“Fructosamine levels provide a retrospective reading of blood glucose for the 2 weeks prior to measurement [30,31].”
BackgroundGut–Brain Axis: Regulation of Glucose Metabolism
Heijboer, A. C., Pijl, H., Van den Hoek, A. M., Havekes, L. M., Romijn, J. A., & Corssmit, E. P. M. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01492.x · Cited by 87 · cited 1×
“food intake and energy balance has substantially improved [9–11].”
BackgroundEbert, R., Nauck, M., & Creutzfeldt, W. (1991) · Hormone and Metabolic Research · doi:10.1055/s-2007-1003745 · Cited by 79 · cited 2×
“Specifically, GIP has been shown to promote triglyceride clearance from the circulation [13,14], a process partly mediated by its ability to stimulate lipoprotein lipase activity [15].”
BackgroundMutilation of RNA phage Qβ virus‐like particles: from icosahedrons to rods
Cielens, I., Ose, V., Petrovskis, I., Strelnikova, A., Renhofa, R., Kozlovska, T., & Pumpens, P. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02061-5 · Cited by 71 · cited 1×
“GIP fragment 1–15 including a GC linker sequence fused to the C-terminus of the GIP fragment (YAEGTFISDYSIAMDGC) was chemically synthesized according to standard procedures and coupled to Qb VLPs as previously described [46,47].”
MethodThe benefits of modest weight loss in type II diabetes.
Bosello, O., Armellini, F., Zamboni, M. M., & Fitchet, M. (1997) · PubMed · Cited by 62
Greenway, F. L., & Caruso, M. K. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.1083 · Cited by 61 · cited 1×
“unpleasant side-effect profiles [5–7].”
Spohn, G., Schwarz, K., Maurer, P., Illges, H., Rajasekaran, N., Choi, Y., Jennings, G. T., & Bachmann, M. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6211 · Cited by 58 · cited 1×
“GIP fragment 1–15 including a GC linker sequence fused to the C-terminus of the GIP fragment (YAEGTFISDYSIAMDGC) was chemically synthesized according to standard procedures and coupled to Qb VLPs as previously described [46,47].”
MethodSelf-citationGIP or not GIP? That is the question
Kieffer, T. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00031-2 · Cited by 56 · cited 2×
“The role of GIP in glucose and lipid metabolism is well documented in several animal species [12,36].”
BackgroundIrwin, N., Gault, V. A., Green, B. D., Greer, B., McCluskey, J. T., Harriott, P., O’Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.110 · Cited by 49 · cited 1×
“Likewise, similar observations were made in lean mice after prolonged treatment with a GIP antagonist [35].”
BackgroundPhysiology of GIP - A Lesson from GIP Receptor Knockout Mice
Yamada, Y., & Seino, Y. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826162 · Cited by 48
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Turcot, V., Lu, Y., Highland, H. M., Schurmann, C., Justice, A. E., Fine, R. S., Bradfield, J. P., Esko, T., Giri, A., Graff, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0011-x · Cited by 409
“Blocking GIP signaling using a vaccination approach in mice on a high-fat diet reduces weight gain, mainly through reduced fat accumulation, mediated by increased energy expenditure 57 .”
Having a word with yourself: neural correlates of self-criticism and self-reassurance.
Longe, O., Maratos, F. A., Gilbert, P., Evans, G., Volker, F., Rockliff, H., & Rippon, G. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.09.019 · Cited by 403
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Metadata
- Authors
- Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P.
- Affiliations
- University of Zurich (CH)
- Corresponding author
- Saudan, Philippe
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-09-09
- Volume
- 3
- Issue
- 9
- Pages
- e3163
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2525840
- OpenAlex
- W2059556576
- Cited by
- 136
- References
- 48
- Citations by year
- 2025: 6 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 11 · 2019: 15 · 2018: 6 · 2017: 9 · 2016: 12 · 2015: 6 · 2014: 7 · 2013: 10 · 2012: 10
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- UWA Profiles and Research Repository (University of Western Australia) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Universität Zürich
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- obesity, glucose-dependent insulinotropic polypeptide, GIP receptor, active immunization, virus-like particles, obesity treatment, high-fat diet, weight gain, fat deposition, impaired glucose tolerance, incretin signaling
- MeSH terms
- Animals, Body Weight, Cricetulus, Gastric Inhibitory Polypeptide, Cricetinae, Homeostasis, Humans, Mice, Inbred C57BL, Mice, Transgenic, Obesity, Vaccines, Signal Transduction, CHO Cells, 3T3 Cells, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.